Payment overview · 2025
General Payments
$296.83
16 reported records · 4 companies
Healthcare provider profile · identity verified
Wayne S Barksdale, MD
Allopathic & Osteopathic Physicians|Family Medicine · OLLA, LA · NPI 1912902453
Verified facts
What the public records show
CMS Open Payments records show Wayne S Barksdale, MD received $296.83 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 60.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $178.55 | 60.1% | 10 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $58.91 | 19.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.37 | 11.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.00 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $296.83 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $139.01 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $139.01 | 6 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $58.91 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.54 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.37 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
139 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 531 | 90 |
| Potassium Chloride | Potassium Chloride | 427 | 68 |
| Gabapentin | Gabapentin | 400 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 361 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 359 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 65 |
| Metformin Hcl | Metformin Hcl | 294 | 53 |
| Losartan Potassium | Losartan Potassium | 292 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 284 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 265 | 46 |
| Furosemide | Furosemide | 257 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 252 | 42 |
| Alprazolam | Alprazolam | 250 | 50 |
| Glimepiride | Glimepiride | 244 | 46 |
| Lisinopril | Lisinopril | 244 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 234 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 28 |
| Tramadol Hcl | Tramadol Hcl | 175 | 30 |
| Omeprazole | Omeprazole | 172 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 31 |
| Meloxicam | Meloxicam | 162 | 26 |
| Montelukast Sodium | Montelukast Sodium | 159 | 28 |
| Allopurinol | Allopurinol | 158 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 23 |
| Eliquis | Apixaban | 139 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 26 |
| Trazodone Hcl | Trazodone Hcl | 135 | 26 |
| Celecoxib | Celecoxib | 125 | 20 |
| Simvastatin | Simvastatin | 122 | 21 |
| Jardiance | Empagliflozin | 121 | 15 |
| Pregabalin | Pregabalin | 113 | 15 |
| Donepezil Hcl | Donepezil Hcl | 108 | 20 |
| Sertraline Hcl | Sertraline Hcl | 106 | 31 |
| Carvedilol | Carvedilol | 104 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 13 |
| Finasteride | Finasteride | 91 | 15 |
| Ozempic | Semaglutide | 89 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 86 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 83 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 12 |
| Temazepam | Temazepam | 77 | 13 |
| Prednisone | Prednisone | 75 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 21 |
| Estradiol | Estradiol | 72 | suppressed |
| Ezetimibe | Ezetimibe | 71 | 14 |
| Januvia | Sitagliptin Phosphate | 71 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 70 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 14 |
| Metformin Hcl Er | Metformin Hcl | 63 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 63 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 13 |
| Atenolol | Atenolol | 59 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 58 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 57 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 57 | 12 |
| Mirtazapine | Mirtazapine | 55 | 11 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Nifedipine Er | Nifedipine | 54 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Torsemide | Torsemide | 54 | 13 |
| Spironolactone | Spironolactone | 53 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | suppressed |
| Trulicity | Dulaglutide | 50 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 40 |
| Glipizide | Glipizide | 45 | suppressed |
| Linzess | Linaclotide | 45 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 19 |
| Glipizide Er | Glipizide | 43 | suppressed |
| Lansoprazole | Lansoprazole | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Baclofen | Baclofen | 40 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | suppressed |
| Famotidine | Famotidine | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 25 |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 24 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | suppressed |
| Indapamide | Indapamide | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | 12 |
| Primidone | Primidone | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Pentoxifylline | Pentoxifylline | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Nabumetone | Nabumetone | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 15 |
| Verapamil Er Pm | Verapamil Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 14 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Cevimeline Hcl | Cevimeline Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tri-Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Cephalexin | Cephalexin | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $296.83 · 16 records | ABBVIE INC. | ELIQUIS, NURTEC ODT, QULIPTA, REXULTI, UBRELVY, VRAYLAR, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error